tiprankstipranks
Trending News
More News >
dorsaVi Limited (AU:DVL)
:DVL
Australian Market
Advertisement

dorsaVi Limited (DVL) AI Stock Analysis

Compare
3 Followers

Top Page

AU:DVL

dorsaVi Limited

(Sydney:DVL)

Rating:45Neutral
Price Target:
AU$0.00
▼(-100.00%Downside)
dorsaVi Limited scores low due to severe financial performance issues, including sustained losses and negative cash flows. Technical analysis provides some positive signs with short-term price momentum, but the valuation remains unattractive due to negative earnings and no dividend yield. Significant financial restructuring is needed for improvement.

dorsaVi Limited (DVL) vs. iShares MSCI Australia ETF (EWA)

dorsaVi Limited Business Overview & Revenue Model

Company DescriptiondorsaVi Ltd engages in the development and sale of motion analysis technologies in Australia, Europe, and the United States. The company provides ViMove+, a clinical and sports solutions; ViSafe, a wearable sensor technology that tracks, analyzes, and reports how workforce moves and reviews and pinpoints unsafe work practices that leads to workplace injury; and myViSafe technology for organizations and on-site clinicians to identify and mitigate injury risk in the workplace and drive behavioral changes. It also offers ViPerform, a wearable and wireless movement sensor technology that offers objective data to assess risk of sport injury, and guides athletic training and recovery programs; telehealth solutions; and professional suites. dorsaVi Ltd was incorporated in 2008 and is based in Oakleigh South, Australia.
How the Company Makes MoneydorsaVi Limited generates revenue through the sale and leasing of its wearable sensor systems and related software solutions. The company's revenue streams include direct sales to healthcare providers, sports organizations, and businesses focused on workplace safety. Additionally, dorsaVi offers subscription-based access to its analytics platform, which provides users with detailed insights and reports on movement and muscle activity. The company also engages in strategic partnerships with organizations in the healthcare and sports sectors to expand its market reach and enhance its product offerings.

dorsaVi Limited Financial Statement Overview

Summary
dorsaVi Limited is facing significant financial challenges with declining revenues, persistent losses, and negative cash flows. The company has a negative gross profit margin, and its operational inefficiencies and inability to generate positive cash flows pose serious concerns.
Income Statement
15
Very Negative
dorsaVi Limited has experienced a decline in revenue and profitability over recent years. The negative gross profit margin indicates the company is selling its products below cost. With consistent negative EBIT and EBITDA margins, the company is struggling to cover its operating expenses. Additionally, the company has not shown any revenue growth in the past year, highlighting significant challenges in its business model and market conditions.
Balance Sheet
30
Negative
The company's balance sheet shows a relatively low debt-to-equity ratio, which suggests moderate leverage. However, the persistent losses have eroded equity over the years, and the return on equity remains negative, indicating inefficiencies in using shareholder funds. The equity ratio shows that equity is a small portion of total assets, hinting at potential solvency issues.
Cash Flow
20
Very Negative
The company has consistently experienced negative free cash flow, indicating it is not generating enough cash to cover its capital expenditures. The operating cash flow is also negative, reflecting challenges in generating cash from core operations. The free cash flow and operating cash flow to net income ratios are unfavorable, suggesting poor cash conversion efficiency.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue1.30M1.75M2.35M1.87M2.02M
Gross Profit1.18M-798.43K-1.45M-1.74M-2.21M
EBITDA-1.60M-1.88M-1.53M-2.29M-6.84M
Net Income-1.25M-1.82M-1.54M-2.41M-7.59M
Balance Sheet
Total Assets2.18M2.69M3.36M5.42M3.83M
Cash, Cash Equivalents and Short-Term Investments478.10K878.72K449.70K2.80M1.69M
Total Debt190.17K321.85K1.18M1.18M1.91M
Total Liabilities1.16M1.01M2.13M2.95M3.37M
Stockholders Equity1.02M1.68M1.22M2.48M459.03K
Cash Flow
Free Cash Flow-622.08K-1.02M-2.25M-2.36M-2.97M
Operating Cash Flow-600.90K-967.41K-2.15M-2.27M-2.18M
Investing Cash Flow-21.18K-51.65K-100.34K-85.41K-788.80K
Financing Cash Flow227.06K1.45M-92.25K3.47M1.89M

dorsaVi Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
€9.09B16.744.09%1.84%4.14%-26.32%
53
Neutral
AU$11.23M-127.39%-17.08%-2263.16%
48
Neutral
AU$4.09M-637.73%-13.05%-184.09%
45
Neutral
AU$22.78M-74.01%-8.28%35.71%
42
Neutral
AU$9.14M-1370.92%-36.98%41.43%
41
Neutral
AU$4.90M-174.80%-50.78%45.67%
39
Underperform
AU$11.14M-50.47%-31.53%-31.70%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:DVL
dorsaVi Limited
0.02
0.01
100.00%
AU:X2M
X2M Connect Limited
0.02
-0.02
-50.00%
AU:BDT
Birddog Technology Ltd.
0.07
>-0.01
-12.50%
AU:HYD
Hydrix Limited
0.02
0.01
100.00%
AU:BCC
Beam Communications Holdings Limited
0.13
-0.03
-18.75%
AU:ZMM
ZIMI Ltd
0.01
0.00
0.00%

dorsaVi Limited Corporate Events

dorsaVi Unveils Breakthrough RRAM Sensor Integration Results
Jul 21, 2025

dorsaVi Limited has announced breakthrough results from its evaluation of RRAM-enabled biomedical sensors, highlighting significant improvements in speed, endurance, and energy consumption metrics. The integration of RRAM technology into dorsaVi’s platforms promises enhanced performance for wearable biomedical devices, offering faster memory access, lower power consumption, and greater endurance, which are crucial for real-world clinical and movement-monitoring applications.

dorsaVi Limited Announces Virtual Extraordinary General Meeting for 2025
Jul 16, 2025

dorsaVi Limited has announced that its 2025 Extraordinary General Meeting will be held virtually on August 15, 2025. Shareholders are encouraged to vote by proxy and submit questions in advance, with the company prepared to make alternative arrangements if necessary. This move reflects the company’s adaptability in managing shareholder engagement and maintaining transparency in its operations.

dorsaVi Limited Calls for Extraordinary General Meeting to Ratify Share Issues
Jul 16, 2025

dorsaVi Limited has announced an Extraordinary General Meeting to be held virtually on August 15, 2025, where shareholders will vote on key resolutions, including the ratification of prior issues of Tranche 1 Placement Shares. This meeting reflects the company’s ongoing efforts to engage shareholders in its strategic decisions and ensure compliance with regulatory requirements, which could impact its financial positioning and stakeholder relations.

dorsaVi Advances Sensor Technology with RRAM Integration
Jul 15, 2025

dorsaVi Limited has announced the validation and integration of its licensed Resistive Random-Access Memory (RRAM) technology, which is expected to significantly enhance the performance of its sensor platforms. The RRAM technology offers high-speed, low-power capabilities suitable for next-generation embedded and edge AI platforms, with potential applications in robotics, adaptive sensing, and advanced edge-AI systems. This advancement positions dorsaVi to lead in real-time movement analysis and explore new markets through strategic partnerships.

DorsaVi Limited Announces Cessation of Securities
Jul 11, 2025

DorsaVi Limited announced the cessation of 3,693,714 securities due to the expiry of options or other convertible securities without exercise or conversion. This cessation may impact the company’s issued capital and could have implications for stakeholders regarding the company’s financial structure and market activities.

dorsaVi Limited Announces Director Departure
Jul 9, 2025

dorsaVi Limited announced that Dr. Michael Winlo has ceased to be a director of the company as of July 3, 2025. The announcement details Dr. Winlo’s holdings in the company, which include 3,251,940 quoted shares and 454,545 unlisted options. This change in directorship may impact the company’s governance and strategic direction, influencing stakeholders’ perceptions and potentially affecting its market positioning.

dorsaVi Embarks on RRAM Sensor Testing to Revolutionize Biomedical Applications
Jul 7, 2025

dorsaVi Limited has initiated testing of its RRAM-powered sensor systems in Singapore, marking a significant step in integrating next-generation Resistive Random-Access Memory into its biomedical sensor platforms. This development is expected to enhance the speed and efficiency of applications like EMG and ECG, addressing limitations of traditional memory systems. The results from this testing will inform potential scaling strategies for various biomedical sensors and open opportunities in AI, robotics, and neuromorphic computing, reinforcing dorsaVi’s leadership in the industry.

dorsaVi Limited Issues 70 Million New Shares
Jul 4, 2025

dorsaVi Limited has announced the issuance of 70,000,000 fully paid ordinary shares, as per the Corporations Act 2001. This move complies with all necessary legal provisions and indicates the company’s ongoing transparency and adherence to regulatory requirements. The issuance of shares could potentially enhance dorsaVi’s financial capabilities, supporting its operations in the motion analysis technology sector and possibly impacting its market position positively.

DorsaVi Limited Quotes 70 Million New Securities on ASX
Jul 4, 2025

DorsaVi Limited has announced the quotation of 70 million fully paid ordinary securities on the Australian Securities Exchange (ASX) as of July 4, 2025. This move is part of previously announced transactions and is expected to enhance the company’s market presence and provide additional capital for its operations, potentially impacting its industry positioning and offering new opportunities for stakeholders.

dorsaVi Director’s Securities Update: Performance Rights Conversion
Jul 4, 2025

dorsaVi Limited has announced a change in the interests of its director, Andrew James Ronchi. The update involves the conversion of 500,000 performance rights into shares, increasing his indirect holdings while the performance rights lapsed. This change reflects an internal adjustment in the director’s securities, potentially impacting the company’s governance and shareholder dynamics.

dorsaVi Ltd Announces Director Resignation and Strategic Shift
Jul 3, 2025

dorsaVi Ltd announced the resignation of Mr. Michael Winlo as Non-Executive Director to focus on other business commitments. The company is shifting its strategic focus to hiring executives and advisers with expertise in RRAM and semiconductor technologies, which is expected to enhance the performance of their sensors. This move is part of dorsaVi’s plan to drive innovation and growth, with the Non-Executive Chairman expressing excitement about the potential of RRAM technology to improve sensor performance.

dorsaVi Limited Issues Over 109 Million Shares in Compliance with Corporations Act
Jun 27, 2025

dorsaVi Limited has issued 109,959,038 fully paid ordinary shares without disclosure to investors as per the Corporations Act. This move signifies the company’s compliance with the necessary legal provisions and indicates no excluded information under the relevant sections of the Corporations Act. The issuance of shares could potentially impact dorsaVi’s market operations and stakeholder interests by enhancing its capital structure and possibly influencing its market positioning.

DorsaVi Limited Announces Cessation of Performance Rights
Jun 27, 2025

DorsaVi Limited announced the cessation of 1,052,500 performance rights due to unmet conditions, effective June 27, 2025. This development may impact the company’s capital structure and could have implications for stakeholders, reflecting on the company’s operational adjustments and strategic focus.

dorsaVi Limited Expands Market Presence with New ASX Quotation
Jun 27, 2025

dorsaVi Limited has announced the quotation of nearly 5 million fully paid ordinary securities on the Australian Securities Exchange (ASX) as of June 27, 2025. This move is part of the company’s strategy to expand its market presence and potentially increase its capital base, which could enhance its operational capabilities and strengthen its position in the wearable sensor technology market.

dorsaVi Limited Announces Quotation of 105 Million Securities on ASX
Jun 27, 2025

dorsaVi Limited announced the quotation of 105,000,000 fully paid ordinary securities on the ASX, effective June 27, 2025. This move is part of previously announced transactions and is expected to enhance the company’s capital structure, potentially impacting its market positioning and offering new opportunities for stakeholders.

dorsaVi Limited Announces Proposed Issue of 20 Million Securities
Jun 12, 2025

dorsaVi Limited has announced a proposed issue of 20 million new securities, specifically options expiring three years from issuance at an exercise price of $0.02. This move is part of a strategic placement aimed at enhancing the company’s financial positioning and operational capabilities, potentially impacting its market presence and offering benefits to stakeholders through increased capital resources.

dorsaVi Limited Announces Proposed Securities Issue
Jun 12, 2025

dorsaVi Limited announced a proposed issue of 60,000,000 ordinary fully paid securities, with the issuance date set for August 1, 2025. This move is part of a placement or other type of issue, which may impact the company’s market positioning by potentially increasing its capital base and providing additional resources for growth and development.

dorsaVi Secures Exclusive License for Advanced RRAM Technology from NTU Singapore
Jun 12, 2025

dorsaVi Limited has secured an exclusive worldwide license for advanced resistive random-access memory (RRAM) technology from NTU Singapore. This strategic acquisition is set to enhance dorsaVi’s sensor technology, offering improved efficiency and extended battery life, positioning the company for growth in high-value markets such as elite sports, rehabilitation, and industrial automation. The integration of RRAM technology into dorsaVi’s products is expected to redefine wearable technology capabilities, providing a competitive edge in the industry.

dorsaVi Limited Initiates Trading Halt for Major Announcement
Jun 10, 2025

dorsaVi Limited has requested a trading halt on its securities pending an important announcement regarding a Worldwide Exclusive RRAM Licence Agreement and a capital raising initiative. This move is aimed at managing its continuous disclosure obligations and is expected to impact the company’s market operations by potentially enhancing its technological capabilities and financial position.

dorsaVi Expands Reach with New SANO Health Partnership
May 30, 2025

dorsaVi has signed a three-year agreement with SANO Health, a leader in mining health solutions, to extend the use of its ViSafe+ technology across remote mining sites in Australia. This partnership aims to enhance dorsaVi’s product offerings in high-risk industries like mining and transport, allowing the company to expand its market reach both domestically and internationally, while providing SANO Health with the tools to improve workplace safety and reduce musculoskeletal injuries.

dorsaVi Expands AI Platform into Workplace Safety Market
May 8, 2025

dorsaVi has expanded its AI-powered movement analysis platform, Video AI, into the workplace ergonomics market, partnering with a major US franchise group and a leading Australian insurer. This strategic move allows dorsaVi to leverage its scalable, high-margin Video AI platform to enter the multibillion-dollar workplace safety and injury prevention market, marking a significant milestone in the company’s product evolution.

dorsaVi Advances AI Movement Analysis and Launches New ACL Injury Test
Apr 30, 2025

dorsaVi Limited has reported significant progress in the commercial release of its AI-powered Video Movement Analysis Platform, gaining traction in the US market. The company has achieved sales revenue of $289k and is advancing security clearances with a major US clinical group, which could expand its market presence. Additionally, dorsaVi has launched a pioneering 3D motion analysis test to address ACL injuries, potentially setting a new standard in sports medicine. A new research collaboration with a prominent US surgeon aims to optimize movement analysis for elite athletes, further reinforcing dorsaVi’s leadership in data security and injury prevention.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 23, 2025